Navigation Links
Astellas Announces Successful Completion of Initial Tender Offer for Shares of OSI and Announces Subsequent Offer Period
Date:6/3/2010

the initial offer period, except that shares tendered during the subsequent offer period may not be tendered by the guaranteed delivery procedure and may not be withdrawn.

Following the expiration of the subsequent offer period, if Astellas owns at least 90% of the issued and outstanding shares of OSI common stock, Astellas intends to complete the acquisition of OSI through the short-form merger procedure under Delaware law, by which the companies can complete the merger without a meeting of OSI's stockholders.  In the merger, each outstanding share of OSI common stock not tendered and purchased in the initial offer period or the subsequent offer period will be converted into the right to receive the same consideration provided in the initial offer, except for such shares for which appraisal rights have been validly asserted.  As a result of the merger, which Astellas expects to close as soon as practicable, OSI's common stock will cease to be traded on the Nasdaq Global Select Market.

Citigroup is acting as exclusive financial advisor to Astellas and Morrison & Foerster LLP is acting as legal counsel.

Additional Information

Further details related to this proposal can be found on www.oncologyleader.com

About Astellas

Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 15,000 employees worldw
'/>"/>

SOURCE Astellas Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting
2. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
3. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
4. Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide
5. Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
6. GSK Announces Revised Product Labels for Serevent® and Advair®
7. US Oncology Announces iKnowMed(TM) Technology Platform
8. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
9. Dendreon Announces Presentation of PROVENGE Data at the American Urological Association Annual Meeting
10. Elbit Imaging Ltd. Announces First Quarter Results for 2010
11. CardioGenics Announces Update Regarding Status of Merck Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014 /PRNewswire-iReach/ -- Dr. Michael Gabriel of a ... to a recent study, which shows how grief in pregnancy ... http://photos.prnewswire.com/prnh/20140723/129709 According to US News ... more likely than others to grow up overweight or obese, ... There were two specific types of stress that caused obesity: ...
(Date:7/24/2014)... HILDEN , Deutschland, und ... , ... ermöglicht QIAGEN die Entwicklung von ... Genpanels, für Blutkrebs  Neuer Test ... Patienten mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen ...
(Date:7/24/2014)... Calif. , July 24, 2014  IRIDEX Corporation ... will release its second quarter 2014 financial results after ... In conjunction with the release, the Company will ... 5:00 p.m. Eastern Time on Thursday, ... the quarter and other business developments. Interested ...
Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
... Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), a ... with inflammation, today announced that enrollment in the Phase ... (ACS) will continue based on the positive outcome of ... safety data. An independent statistician completed ...
... announced that it has secured an exclusive license for ... existing clinical work whereby a medicated tampon was used ... States patents. Joseph Fuisz, Managing Partner of ... acquisition, having had a long standing interest in vaginal ...
Cached Medicine Technology:Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl 2Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl 3Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl 4
(Date:7/25/2014)... FRIDAY, July 25, 2014 (HealthDay News) -- Seniors are ... younger people, a new study finds. "Almost any ... memory from the age of 25 on," study co-author ... in a university news release. However, Martin said, ... impact on processing in older adults compared with younger ...
(Date:7/25/2014)... 2014 Sport Court® provided ... Nike National Invitational Tournament (NIT) in Chicago ... Junior National Tournament (USJN) in Washington D.C. at ... for these prestigious national tournaments included 44 Sport Court ... of playing surface at McCormick Place for the NIT, ...
(Date:7/25/2014)... Providence, Rhode Island (PRWEB) July 25, 2014 ... very pleased to announce that Dr. Kerri Luzzo, Lead ... Under Forty Award" for her professional accomplishments in fertility ... (PBM). , At the 10th Annual PBN Awards ... Newport, Rhode Island, 40 of the most highly regarded, ...
(Date:7/25/2014)... 25, 2014 Florida Hospital and MOSI officially ... organizations for years to come and make a difference in ... $2 million dollar check to provide the support needed to ... enable MOSI to transform the IMAX Dome Theatre from film ... the only IMAX Dome Theatre in the state of Florida, ...
(Date:7/25/2014)... FRIDAY, July 25, 2014 (HealthDay News) -- The human ... effects of dehydration, a new study finds. ... researchers in England have found that the brain compensates ... the blood. "This research has helped us understand ... to extreme exercise in extreme conditions," study first author ...
Breaking Medicine News(10 mins):Health News:Distractions Seem More Troublesome With Age 2Health News:Sport Court Provides All Sports Flooring for Basketball Events in Chicago and Washington D.C. 2Health News:Dr. Kerri Luzzo of the Reproductive Science Center of Providence Receives “40 Under Forty Award" for Outstanding Professional Accomplishments and Community Outreach 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4Health News:Human Brain Has Coping Mechanism for Dehydration 2
... about three-quarters of whites, Hispanics, CDC says , THURSDAY, ... powers of breast-feeding aren,t reaching black American women as ... study from the U.S. Centers for Disease Control and ... more than 80 percent of Hispanic mothers attempt to ...
... tumors escape the body,s natural immune surveillance has recently been ... The study shows how tumors can create a tolerant microenviroment ... features of lymph nodes. The discovery, published in Science ... 2010, underscores the role of the lymphatic system in cancer ...
... ... About Malaria Prevention Aboard an Eco-Friendly Bus , ... Atlanta, GA (Vocus) March 25, 2010 -- The United Nations Foundation,s ... announced today the launch of its Nothing But Nets Buzz Tour. The campaign will take ...
... ... cell-based strategy to treat motor symptoms in rats with a disease designed to mimic Parkinson,s ... San Francisco, CA ... motor symptoms in rats with a disease designed to mimic Parkinson,s disease., , , , ...
... 33 percent higher risk of death, study finds, , ... do much better, in terms of survival, if they ... need, new research suggests. , The study found that ... need help from others have a 33 percent increased ...
... at the Eastern Virginia Medical School Strelitz Diabetes Center ... of Defense (DoD) Peer Reviewed Medical Research Program to ... Type 1 diabetes. David Taylor-Fishwick, PhD, ... Cell, Molecular and Islet Biology Laboratory, leads the team ...
Cached Medicine News:Health News:Black Women Least Likely to Breast-Feed in U.S. 2Health News:Black Women Least Likely to Breast-Feed in U.S. 3Health News:Tumors hide out from the immune system by mimicking lymph nodes 2Health News:Grassroots Campaign Drives toward Ending Malaria Deaths by 2015 2Health News:Grassroots Campaign Drives toward Ending Malaria Deaths by 2015 3Health News:Novel Parkinson's Treatment Strategy Involves Cell Transplantation 2Health News:Novel Parkinson's Treatment Strategy Involves Cell Transplantation 3Health News:Novel Parkinson's Treatment Strategy Involves Cell Transplantation 4Health News:Accepting Help Improves Survival Among Diabetics 2Health News:Accepting Help Improves Survival Among Diabetics 3Health News:EVMS receives more than $1 million in federal funds to develop new ways to reverse type 1 diabetes 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: